The FDA has granted approval to tepotinib (Tepmetko) for adult patients with metastatic non–small cell lung cancer harboring MET exon 14 skipping alterations.
More than a thousand Australians will have access to cheaper medicines from next month under new listings to the Pharmaceutical Benefits Scheme announced by Health Minister Mark Butler.
TEPMETKO is the first and only oral MET inhibitor to be approved in the European Economic Area for treating adult patients with advanced NSCLC harboring alterations leading to METex14 skipping,
Merck, a leading science and technology company, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending approval of once-daily oral TEPMETKO®